In summary, METTL16 promotes breast cancer progression by regulating FBXO5-mediated proliferation and EMT as well as GPX4-mediated ferroptosis resistance, and targeting METTL16 via advanced nanoparticle-based delivery represents a promising therapeutic strategy for TNBC. This evidence concerns the gene FBXO5 and breast cancer.